Hoth Therapeutics Announces Expansion of Clinical Sites for HT-001 Phase 2a Trial

PR Newswire09-05

Dana-Farber Cancer Institute in Boston, MA and Montefiore Medical Center in New York, NY Join Clinical Trial NEW YORK, Sept. 5, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2465523687?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/rdaGJVxssbv4muuTO7wP_A--~B/aD02ODt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/a168928171a9653a66d38f6c5e666beb","is_english":true,"pubTime":"2024-09-05 22:32","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2465523687","market":"us","top_or_hot":-1,"title":"Hoth Therapeutics Announces Expansion of Clinical Sites for HT-001 Phase 2a Trial","media":"PR Newswire","content":"<div>\n<p>Dana-Farber Cancer Institute in Boston, MA and Montefiore Medical Center in New York, NY Join Clinical Trial\nNEW YORK, Sept. 5, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-...</p>\n\n<a href=\"https://finance.yahoo.com/news/hoth-therapeutics-announces-expansion-clinical-143200012.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hoth Therapeutics Announces Expansion of Clinical Sites for HT-001 Phase 2a Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHoth Therapeutics Announces Expansion of Clinical Sites for HT-001 Phase 2a Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-09-05 22:32 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/hoth-therapeutics-announces-expansion-clinical-143200012.html><strong>PR Newswire</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Dana-Farber Cancer Institute in Boston, MA and Montefiore Medical Center in New York, NY Join Clinical Trial\nNEW YORK, Sept. 5, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-...</p>\n\n<a href=\"https://finance.yahoo.com/news/hoth-therapeutics-announces-expansion-clinical-143200012.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HOTH","symbol_name":"Hoth Therapeutics","start_time":0,"source_url":"https://finance.yahoo.com/news/hoth-therapeutics-announces-expansion-clinical-143200012.html","article_id":"2465523687","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/rdaGJVxssbv4muuTO7wP_A--~B/aD02ODt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/a168928171a9653a66d38f6c5e666beb"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/hoth-therapeutics-announces-expansion-clinical-143200012.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2465523687","pubTimestamp":1725546720,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Dana-Farber Cancer Institute in Boston, MA andMontefiore Medical Center in New York, NY Join Clinical Trial. NEW YORK, Sept. 5, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. , a patient-focused biopharmaceutical company, today announced today that it has received Institutional Review Board approval from theMontefiore Medical Center and the Dana-Farber Cancer Institute to proceed with its First-in-Human Phase 2a clinical trial of HT-001for the treatment of skin toxicities associated with Epidermal Growth Factor Receptor Inhibitors .\"We are very pleased to have received approval from these two world class medical centers for our FIH clinical trial,\" said Hoth Therapeutics Chief Executive Officer,Robb Knie. \"We are hopeful that this trial will demonstrate successful delivery of our lead therapeutic candidate HT-001 and bring hope to cancer patients suffering from skintoxicities associated with EGFRi treatments.\" Knie further stated, \"Hoth ended the prior quarter with over $9 million in cas","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"HOTH":"Hoth Therapeutics","BK4007":"制药","BK4181":"酒店及度假村房地产投资信托","HT":"HT基金","BK4218":"酒店及度假村房地产信托"},"translate_title":"Hoth Therapeutics宣布扩大HT-001 2a期试验的临床地点","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HOTH":1,"HT":1},"content_text":"Dana-Farber Cancer Institute in Boston, MA and Montefiore Medical Center in New York, NY Join Clinical Trial\nNEW YORK, Sept. 5, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced today that it has received Institutional Review Board approval from the Montefiore Medical Center and the Dana-Farber Cancer Institute to proceed with its First-in-Human (FIH) Phase 2a clinical trial of HT-001 for the treatment of skin toxicities associated with Epidermal Growth Factor Receptor Inhibitors (EGFRi).\n\n  \n\n\"We are very pleased to have received approval from these two world class medical centers for our FIH clinical trial,\" said Hoth Therapeutics Chief Executive Officer, Robb Knie. \"We are hopeful that this trial will demonstrate successful delivery of our lead therapeutic candidate HT-001 and bring hope to cancer patients suffering from skin toxicities associated with EGFRi treatments.\" Knie further stated, \"Hoth ended the prior quarter with over $9 million in cash and has no plans for further capital raise in 2024.\"\nThis Phase 2a dose- ranging study to investigate the efficacy, safety, and tolerability of topical HT-001 for the treatment of skin toxicities associated with EGFRi. More information can be found at clinicaltrials.gov.\nAbout Hoth Therapeutics, Inc.  \nHoth Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative, impactful, and ground-breaking treatments with a goal to improve patient quality of life. We are a catalyst in early-stage pharmaceutical research and development, elevating drugs from the bench to pre-clinical and clinical testing. Utilizing a patient-centric approach, we collaborate and partner with a team of scientists, clinicians, and key opinion leaders to seek out and investigate therapeutics that hold immense potential to create breakthroughs and diversify treatment options. To learn more, please visit https://ir.hoththerapeutics.com/.\nForward-Looking Statement\nThis press release includes forward-looking statements based upon Hoth's current expectations, which may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws, and are subject to substantial risks, uncertainties, and assumptions. These statements concern Hoth's business strategies; the timing of regulatory submissions; the ability to obtain and maintain regulatory approval of existing product candidates and any other product candidates we may develop, and the labeling under any approval we may obtain; the timing and costs of clinical trials, and the timing and costs of other expenses; market acceptance of our products; the ultimate impact of the current coronavirus pandemic, or any other health epidemic, on our business, our clinical trials, our research programs, healthcare systems, or the global economy as a whole; our intellectual property; our reliance on third-party organizations; our competitive position; our industry environment; our anticipated financial and operating results, including anticipated sources of revenues; our assumptions regarding the size of the available market, benefits of our products, product pricing, and timing of product launches; management's expectation with respect to future acquisitions; statements regarding our goals, intentions, plans, and expectations, including the introduction of new products and markets; and our cash needs and financing plans. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. You should not place reliance on these forward-looking statements, which include words such as \"could,\" \"believe,\" \"anticipate,\" \"intend,\" \"estimate,\" \"expect,\" \"may,\" \"continue,\" \"predict,\" \"potential,\" \"project\" or similar terms, variations of such terms, or the negative of those terms. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee such outcomes. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described in the section titled \"Risk Factors\" in Hoth's most recent Annual Report on Form 10-K and Hoth's other filings made with the U. S. Securities and Exchange Commission. All such statements speak only as of the date made. Consequently, forward-looking statements should be regarded solely as Hoth's current plans, estimates, and beliefs. Investors should not place undue reliance on forward-looking statements. Hoth cannot guarantee future results, events, levels of activity, performance, or achievements. Hoth does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events, or circumstances or to reflect the occurrences of unanticipated events, except as may be required by applicable law.\nInvestor Contact: LR Advisors LLC Email: investorrelations@hoththerapeutics.comwww.hoththerapeutics.comPhone: (678) 570-6791\n View original content to download multimedia:https://www.prnewswire.com/news-releases/hoth-therapeutics-announces-expansion-of-clinical-sites-for-ht-001-phase-2a-trial-302239554.html\nSOURCE Hoth Therapeutics, Inc.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2465523687"}